ReviewBiomedicines2025

PD-L1 Inhibitor Cosibelimab for Cutaneous Squamous Cell Carcinoma: Comprehensive Evaluation of Efficacy, Mechanism, and Clinical Trial Insights.

Omer A Idris et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.